Why is "Lonza Group" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-24 22:45:30
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Lonza_Group entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-24 and was most recently seen on 2026-07-24.
Wikipedia Overview
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Lonza Group (LONN) Q3 2024 TU earnings summary - quartr.com
-
Lonza Group AG 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:LZAGY) 2026-07-22 - Seeking Alpha
-
Lonza Group Ltd (LONN) Gets a Buy from Bernstein - The Globe and Mail
-
Can Lonza Group (SWX:LONN) Justify Its Valuation On Raised Margin Guidance? - simplywall.st
-
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings? - Yahoo Finance
-
Lonza Group Ltd (LZAGF) (H1 2026) Earnings Call Highlights: Stro - GuruFocus
-
Lonza Group: Mixed results as Integrated Biologics' growth offsets strong operating performance - marketscreener.com
-
Lonza Group stock holds steady as investors await fresh signals - AD HOC NEWS
-
Lonza shares hit late-June low as revenue miss overshadows raised margin outlook - Investing.com
-
Goldman Sachs Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
-
Lonza Group AG Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
-
Microsize, Schedio link to buy Lonza's Swiss micronization plant - Fierce Pharma
-
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Yahoo Finance
-
Lonza Group Continues To Leverage Biopharma’s Optimization Push (OTCMKTS:LZAGY) - Seeking Alpha
-
Is It Too Early To Reconsider Lonza Group (SWX:LONN) After Recent Share Price Swings? - simplywall.st
-
Lonza Group Ltd (LONN) Receives a Buy from UBS - The Globe and Mail
-
Lonza Group AG Expands Strategic Collaboration With Leading US Biopharmaceutical Company - marketscreener.com
-
Lonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed? - simplywall.st
-
Lonza Lifts 2026 Margin Outlook as CDMO Strategy and ADC Investments Drive Strong Half-Year Results - The Globe and Mail
-
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)? - simplywall.st
-
We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt - simplywall.st
-
CDMOs dominate the headlines – and Lonza delivers a clear message of strength - European Biotechnology Magazine
-
Swiss CDMO giant Lonza group to set up GCC in Hyd - The Times of India
-
Lonza Group AG to set up GCC in Hyderabad - The Hindu
-
Lone Star, Altaris, One Rock Said Among Bidders for Lonza Assets - Bloomberg
-
Lonza Group AG to setup GCC in Hyderabad - Deccan Herald
-
Lonza Bets On A Pure-Play CDMO Reset - Finimize
-
Lonza Group to set up new GCC in Hyderabad - BusinessLine
-
Lonza to Establish GCC in Hyderabad to Strengthen Telangana’s Life Sciences Ecosystem? - analyticsindiamag.com
-
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - Yahoo Finance
-
Lonza Group AG's (VTX:LONN) largest shareholders are individual investors with 56% ownership, institutions own 44% - Yahoo Finance
-
Lonza Group AG (VTX:LONN) most popular amongst individual investors who own 51% of the shares, institutions hold 49% - Yahoo Finance
-
Top 10 Contract Development and Manufacturing Organizations 2025 - Genetic Engineering and Biotechnology News
-
Lonza Group Welcomes New CEO - contractpharma.com
-
Lonza Group AG Revenue Breakdown – MIL:1LONN - TradingView
-
Lonza Group AG Restates 2025 HY Financials Includes Updated Consolidated Income Statement And Key Performance Measures - TradingView
-
Switzerland: Appropriate time for Lonza Group to exit capsules business could be nearing - Investors in Healthcare
-
Jefferies Sticks to Its Buy Rating for Lonza Group Ltd (LONN) - The Globe and Mail
-
Lonza Group Ltd (LONN) Receives a Buy from RBC Capital - The Globe and Mail
-
Lonza Group Ltd (LONN) Gets a Buy from RBC Capital - The Globe and Mail
-
RBC Capital Keeps Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
-
USA Cell Therapy Manufacturing Market Highlights Lonza Group as Global Market Reaches USD 23.2 Billion by 2036 at 14.1% CAGR | Future Market Insights - The AI Journal
-
Lonza Group AG (VTX:LONN) surges 3.4%; individual investors who own 52% shares profited along with institutions - simplywall.st
-
While Lonza's sales slipped in '24, CDMO touts stronger position heading into new year - Fierce Pharma
-
Lonza Group Calms Concerns About US Tariff Impact - Finimize
-
Lonza to boost gelatin capsule capacity in India, China as it looks to shed the division - Fierce Pharma
-
LONN Stock Price and Chart — SIX:LONN - TradingView
-
Here's Why I Think Lonza Group (VTX:LONN) Is An Interesting Stock - Yahoo Finance
-
Net margin % of Lonza Group AG – SIX:LONN - TradingView
-
Swiss company Lonza Group seeking to acquire CRO Catalent: report - biopharmadive.com
-
Arxada completes first-ever merger deal since split from Lonza Group - Cosmetics Business
-
Lonza-Group-adds-resins-laboratory-in-Georgia - Plastics News
-
Swiss pharma firm Lonza's profit falls less than feared, shares rise - Reuters
-
Worldwide Virus Filtration Industry to 2026 - Featuring Asahi Kasei Medical, Clean Cells and Lonza Group Among Others - PR Newswire
-
Lonza Appoints Maria Soler Nunez as Head of Group Operations - Technology Networks
-
Lonza Group AG: Target Price Consensus and Analysts Recommendations | LONN | CH0013841017 - marketscreener.com
-
Lonza Group AG to buy Capsugel from KKR & Co for $5.5bn - Financier Worldwide
-
Arxada and Troy merge to create microbial control powerhouse - Cosmetics Business
-
Should I buy Lonza Group (LZAGY) - Zacks Investment Research
-
SBI Mutual Fund buys into Swiss drug ingredients maker Lonza Group in January - CNBC TV18
-
Lonza Group (LZAGY) - Zacks Investment Research
-
Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion - Reuters
-
Lonza appoints new CEO - Indian Chemical News
-
Lonza Specialty Chemicals rebrands as Arxada - Indian Chemical News
-
Lonza to buy drug production facility in Switzerland from Novartis - The Straits Times
-
Philippe Deecke appointed CFO of Lonza - Indian Chemical News
-
Lonza Group plans knowledge centre in Hyderabad - Projects Today
-
Lonza To Establish Global Capability Centre In Hyderabad - Passionate In Marketing
-
Lonza to set up India global capability centre - Business Today
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.